<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744965</url>
  </required_header>
  <id_info>
    <org_study_id>032011-086</org_study_id>
    <secondary_id>042008-058</secondary_id>
    <nct_id>NCT00744965</nct_id>
    <nct_alias>NCT00942552</nct_alias>
  </id_info>
  <brief_title>Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo</brief_title>
  <official_title>A Randomized Controlled Clinical Trial of Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized prospective trial which addresses the question of whether use of an oral
      hypoglycemic agent as an adjunct to diet therapy in women with mild gestational diabetes will
      result in achieving euglycemia in a shorter period of time and, in turn, result in less
      frequent maternal and neonatal morbidities. This study is designed to test the hypothesis
      that in women with mild GDM, use of Glyburide in addition to diet and nutritional counseling
      lowers mean infant birth weight by 200 grams as compared with diet and nutritional counseling
      alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2008</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Fetal Weight at Birth</measure>
    <time_frame>Immediately after delivery of fetus</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Large for Gestational Age Infants</measure>
    <time_frame>After delivery</time_frame>
    <description>Birth weight exceeding the 90th percentile for the gestational age at delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrosomia</measure>
    <time_frame>After delivery</time_frame>
    <description>birth weight 4,000 g or greater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Intensive Care Unit Admissions</measure>
    <time_frame>Until hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Cesarean Delivery</measure>
    <time_frame>After delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of Pregnancy-induced Hypertension</measure>
    <time_frame>until hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shoulder Dystocia</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Insulin Treatment</measure>
    <time_frame>after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3rd or 4th Degree Perineal Laceration</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chorioamnionitis</measure>
    <time_frame>intrapartum</time_frame>
    <description>Maternal fever &gt;=38.0°C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Insulin Therapy</measure>
    <time_frame>throughout pregnancy and delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">395</enrollment>
  <condition>Mild Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>Glyburide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women with mild gestational diabetes will be started ADA diet and placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyburide</intervention_name>
    <description>Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
    <arm_group_label>Glyburide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sham dose adjustments of the placebo will be made.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A glucose value of ≥140 mg/dl on a 50-gram oral glucose loading test by plasma at
             gestational age between 24 weeks 0 days and 27 weeks 6 days based on clinical
             information

          -  An Abnormal 3-hour oral glucose tolerance test with a fasting glucose of ≤105 mg/dl

          -  Gestational age of less than or equal to 28 weeks and 0 days at the time of
             consent/randomization

          -  Singleton gestation

        Exclusion Criteria:

          -  Established pregestational diabetes

          -  Abnormal gestational diabetes testing (≥140) prior to 24 weeks 0 days of gestation.
             Women who have a negative glucose loading test (&lt;140mg/dl) before 24 weeks may still
             be considered for this study if they present again for glucose tolerance testing
             between 24 and 27 weeks.

          -  Multiple gestations

          -  Known major fetal anomaly or fetal demise

          -  Any renal disease with serum creatinine of &gt;1.0

          -  Known liver disease such as hepatitis

          -  Maternal or fetal conditions likely to require imminent or very preterm delivery such
             as preeclampsia, preterm premature rupture of the membranes, preterm labor, and
             intrauterine fetal growth restriction

          -  Known hypersensitivity or allergic reaction to Glyburide
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Parkland Memorial Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Casey BM, Duryea EL, Abbassi-Ghanavati M, Tudela CM, Shivvers SA, McIntire DD, Leveno KJ. Glyburide in Women With Mild Gestational Diabetes: A Randomized Controlled Trial. Obstet Gynecol. 2015 Aug;126(2):303-9. doi: 10.1097/AOG.0000000000000967.</citation>
    <PMID>26241419</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 29, 2008</study_first_submitted>
  <study_first_submitted_qc>August 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2008</study_first_posted>
  <results_first_submitted>March 21, 2019</results_first_submitted>
  <results_first_submitted_qc>March 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2020</results_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Kenneth Leveno</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
        </group>
        <group group_id="P2">
          <title>Glyburide</title>
          <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glyburide</title>
          <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="189"/>
            <count group_id="B2" value="186"/>
            <count group_id="B3" value="375"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="375"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="6"/>
                    <measurement group_id="B2" value="31.2" spread="6"/>
                    <measurement group_id="B3" value="31.2" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="375"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Fetal Weight at Birth</title>
        <time_frame>Immediately after delivery of fetus</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
          </group>
          <group group_id="O2">
            <title>Glyburide</title>
            <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Fetal Weight at Birth</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3355" spread="521"/>
                    <measurement group_id="O2" value="3322" spread="481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Large for Gestational Age Infants</title>
        <description>Birth weight exceeding the 90th percentile for the gestational age at delivery.</description>
        <time_frame>After delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
          </group>
          <group group_id="O2">
            <title>Glyburide</title>
            <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Large for Gestational Age Infants</title>
          <description>Birth weight exceeding the 90th percentile for the gestational age at delivery.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Macrosomia</title>
        <description>birth weight 4,000 g or greater</description>
        <time_frame>After delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
          </group>
          <group group_id="O2">
            <title>Glyburide</title>
            <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Macrosomia</title>
          <description>birth weight 4,000 g or greater</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Intensive Care Unit Admissions</title>
        <time_frame>Until hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
          </group>
          <group group_id="O2">
            <title>Glyburide</title>
            <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Intensive Care Unit Admissions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Cesarean Delivery</title>
        <time_frame>After delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
          </group>
          <group group_id="O2">
            <title>Glyburide</title>
            <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Cesarean Delivery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diagnosis of Pregnancy-induced Hypertension</title>
        <time_frame>until hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
          </group>
          <group group_id="O2">
            <title>Glyburide</title>
            <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnosis of Pregnancy-induced Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shoulder Dystocia</title>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
          </group>
          <group group_id="O2">
            <title>Glyburide</title>
            <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Shoulder Dystocia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Insulin Treatment</title>
        <time_frame>after delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
          </group>
          <group group_id="O2">
            <title>Glyburide</title>
            <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Insulin Treatment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>3rd or 4th Degree Perineal Laceration</title>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
          </group>
          <group group_id="O2">
            <title>Glyburide</title>
            <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>3rd or 4th Degree Perineal Laceration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chorioamnionitis</title>
        <description>Maternal fever &gt;=38.0°C</description>
        <time_frame>intrapartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
          </group>
          <group group_id="O2">
            <title>Glyburide</title>
            <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Chorioamnionitis</title>
          <description>Maternal fever &gt;=38.0°C</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Insulin Therapy</title>
        <time_frame>throughout pregnancy and delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
          </group>
          <group group_id="O2">
            <title>Glyburide</title>
            <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Insulin Therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>approximately 3-4 months (throughout the duration of study participation)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Women with mild gestational diabetes will be started ADA diet and placebo.
Placebo: Sham dose adjustments of the placebo will be made.</description>
        </group>
        <group group_id="E2">
          <title>Glyburide</title>
          <description>Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>facial swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size of 395 limits our ability to analyze the effect of Glyburide on uncommon pregnancy outcomes. The study was underpowered for outcomes other than birth weight difference.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kenneth J. Leveno, MD</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-648-2316</phone>
      <email>kenneth.leveno@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

